Table 1. Characteristics of studied subjects.
| Characteristic | BCP | CP | |
|---|---|---|---|
| n = 29 | n = 29 | ||
| Age Group, years (Average ± SD) | 51 ± 8 | 50 ± 7 | |
| BMI, Kg/m2(Average ± SD) | 26 ± 3 | 27 ± 3 | |
| Diagnosis | IDC | 19 (65.5%) | NA |
| ILC | 10 (34.5%) | NA | |
| Stage | I | 3 (10.3%) | NA |
| II | 15 (51.7%) | NA | |
| III | 11 (37.9%) | NA | |
| ER status | pos | 19 (65.5%) | NA |
| neg | 10 (34.5%) | NA | |
| PR status | pos | 12 (41.4%) | NA |
| neg | 17 (58.6%) | NA | |
| HER2 status | pos | 6 (20.7%) | NA |
| neg | 23 (79.3%) | NA | |
| Surgery | Yes | 24 (82.8%) | NA |
| No | 5 (17.2%) | NA | |
| Chemotherapy | Yes | 27 (93.1%) | NA |
| No | 2 (6.9%) | NA | |
| Radiotherapy | Yes | 22 (75.9%) | NA |
| No | 7 (24.1%) | NA | |
| Hormonal Therapy | Yes | 15 (51.7%) | NA |
| no | 14 (48.1%) | NA | |
IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2; NA: not applicable.